Last reviewed · How we verify
NCT03087344
Postprandial Liver and Spleen Stiffness Measurements in the Noninvasive Diagnosis of Cirrhosis
NA trial testing Fibroscan and Acoustic Radiation Force Impulse in Chronic Liver Disease in 22 participants. Completed in 30 June 2018.
30 June 2018
Quick facts
| Lead sponsor | VA Connecticut Healthcare System |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 22 |
| Start date | 31 October 2017 |
| Primary completion | 30 June 2018 |
| Estimated completion | 30 June 2018 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Fibroscan and Acoustic Radiation Force Impulse
- Fibroscan
- Acoustic Radiation Force Impulse
Conditions studied
- Chronic Liver Disease — all drugs for Chronic Liver Disease →
Sponsor
VA Connecticut Healthcare System — full company profile →
Who can join
Adults 18 to 85, any sex, with Chronic Liver Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a study that will evaluate the utility of measuring liver and spleen stiffness before and after a meal by a non invasive ultrasound based technologies called Fibroscan (Transient elastography) and acoustic radio-frequency impulse (ARFI) in diagnosing or excluding cirrhosis in patients with chronic liver disease who will be getting a liver biopsy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03087344
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Chronic Liver Disease
Currently open trials in the same condition.
- NCT06592820 — Endoscopic Ultrasound Shear Wave Elastography Study · recruiting
- NCT06318949 — Albumin Modifications as Early Biomarkers of Chronic Liver Diseases · NA · recruiting
- NCT06743464 — Effect of Perioperative Oral Rifaximin on Early Graft Dysfunction in Adult Living Donor Liver Transplant · NA · recruiting
- NCT06587568 — Mobile Chat Messaging for Alcohol Reduction in Patients With Chronic Liver Diseases · NA · active not recruiting
- NCT06493799 — In Patients With Chronic Liver Diseases(Alcoholic Liver Disease and Non-Alcoholic Fatty Liver Disease), LAENNEC(Human Pl · Phase 3 · recruiting
Other VA Connecticut Healthcare System trials
Trials by the same sponsor.
- NCT04044534 — Intranasal Insulin for Posttraumatic Stress Disorder · Phase 2 · recruiting
- NCT03329157 — Rebuilding Bridges for Homeless Veterans · NA · withdrawn
- NCT05042102 — Donepezil and Cognitive Training for Alcohol Use Disorder (AUD) · Phase 2 · recruiting
- NCT05093556 — Interactive CBT for Headache And Relaxation Training · NA · terminated
- NCT04318639 — The Combination of Donepezil and Cognitive Training for Treating Alcohol Use Disorder · Phase 2, PHASE3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03087344 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by VA Connecticut Healthcare System
- Last refreshed: 5 September 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03087344.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing